{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:30:18Z","timestamp":1790044218812,"version":"4.0.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI157758"],"award-info":[{"award-number":["R01-AI157758"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-AI050410"],"award-info":[{"award-number":["P30-AI050410"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01-AI125087"],"award-info":[{"award-number":["K01-AI125087"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AI007001"],"award-info":[{"award-number":["T32-AI007001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Comparisons of treatments, interventions, or exposures are of central interest in epidemiology, but direct comparisons are not always possible, due to practical or ethical reasons. Here, we detail a fusion approach to compare treatments across studies. The motivating example entails comparing the risk of the composite outcome of death, AIDS, or greater than a 50% CD4 cell count decline in people with HIV when assigned antiretroviral triple vs monotherapy, using data from the AIDS Clinical Trial Group (ACTG) 175 (monotherapy vs dual therapy) and ACTG 320 (dual vs triple therapy). We review a set of identification assumptions and estimate the risk difference using an inverse probability weighting estimator that leverages the shared trial arms (dual therapy). A fusion diagnostic based on comparing the shared arms is proposed that may indicate violation of the identification assumptions. Application of the data fusion estimator and diagnostic to the ACTG trials indicates triple therapy results in a reduction in risk, compared with monotherapy, in individuals with baseline CD4 cell counts between 50 and 300 cells mm\u22123. Bridged treatment comparisons address questions that none of the constituent data sources could address alone, but valid fusion-based inference requires careful consideration of the underlying assumptions.<\/jats:p>","DOI":"10.1093\/aje\/kwae340","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T15:20:44Z","timestamp":1724858444000},"page":"1687-1694","source":"Crossref","is-referenced-by-count":4,"title":["Bridged treatment comparisons: an illustrative application in HIV treatment"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9932-1095","authenticated-orcid":false,"given":"Paul N","family":"Zivich","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina , Chapel Hill, NC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina , Chapel Hill, NC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1741-335X","authenticated-orcid":false,"given":"Jessie K","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina , Chapel Hill, NC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9506-4047","authenticated-orcid":false,"given":"Bonnie E","family":"Shook-Sa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina , Chapel Hill, NC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5568-2510","authenticated-orcid":false,"given":"Alexander","family":"Breskin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina , Chapel Hill, NC ,","place":["United States"]},{"name":"Regeneron Pharmaceuticals , Tarrytown, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9106-4194","authenticated-orcid":false,"given":"Michael G","family":"Hudgens","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina , Chapel Hill, NC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"issue":"8","key":"2026031905361598800_ref1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.rec.2013.11.016","article-title":"The transitive property across randomized controlled trials: if B is better than A, and C is better than B, will C Be better than A?","volume":"67","author":"Catal\u00e1-L\u00f3pez","year":"2014","journal-title":"Rev Esp Cardiol"},{"issue":"1","key":"2026031905361598800_ref2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"issue":"16","key":"2026031905361598800_ref3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"issue":"15","key":"2026031905361598800_ref4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJM199610103351501","article-title":"A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter","volume":"335","author":"Hammer","year":"1996","journal-title":"N Engl J Med"},{"issue":"11","key":"2026031905361598800_ref5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"2026031905361598800_ref6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/aje\/kwac067","article-title":"Illustration of two fusion designs and estimators","volume":"192","author":"Cole","year":"2023","journal-title":"Am J Epidemiol"},{"issue":"13","key":"2026031905361598800_ref7","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1002\/sim.8963","article-title":"Fusion designs and estimators for treatment effects","volume":"40","author":"Breskin","year":"2021","journal-title":"Stat Med"},{"key":"2026031905361598800_ref8","author":"Zivich","year":"26, 2021"},{"issue":"5","key":"2026031905361598800_ref9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/EDE.0000000000001234","article-title":"Defining and identifying per-protocol effects in randomized trials","volume":"31","author":"Rudolph","year":"2020","journal-title":"Epidemiology"},{"issue":"7","key":"2026031905361598800_ref10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/jech.2004.029496","article-title":"Estimating causal effects from epidemiological data","volume":"60","author":"Hern\u00e1n","year":"2006","journal-title":"J Epidemiol Community Health"},{"issue":"6","key":"2026031905361598800_ref11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/aje\/kwp436","article-title":"Invited commentary: positivity in practice","volume":"171","author":"Westreich","year":"2010","journal-title":"Am J Epidemiol"},{"key":"2026031905361598800_ref12","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2207.05010","article-title":"Positivity: identifiability and estimability","author":"Zivich","year":"11, 2022"},{"issue":"1","key":"2026031905361598800_ref13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/EDE.0b013e31818ef366","article-title":"The consistency statement in causal inference: a definition or an assumption?","volume":"20","author":"Cole","year":"2009","journal-title":"Epidemiology"},{"key":"2026031905361598800_ref14","doi-asserted-by":"publisher","DOI":"10.1201\/9781420011579.ch23","volume-title":"Longitudinal Data Analysis. Handbook of Modern Statistical Methods","author":"Robins","year":"2008"},{"issue":"2","key":"2026031905361598800_ref15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B Methodol"},{"issue":"2","key":"2026031905361598800_ref16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.2517-6161.1972.tb00900.x","article-title":"Discussion of Professor Cox\u2019s paper","volume":"34","author":"Breslow","year":"1972","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"4","key":"2026031905361598800_ref17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10985-007-9048-y","article-title":"On the Breslow estimator","volume":"13","author":"Lin","year":"2007","journal-title":"Lifetime Data Anal"},{"key":"2026031905361598800_ref18","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-21700-0","volume-title":"Unified Methods for Censored Longitudinal Data and Causality","author":"Van Der Laan","year":"2003"},{"issue":"5","key":"2026031905361598800_ref19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/sim.5991","article-title":"Variance reduction in randomised trials by inverse probability weighting using the propensity score","volume":"33","author":"Williamson","year":"2014","journal-title":"Stat Med"},{"issue":"1","key":"2026031905361598800_ref20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13063-022-06097-z","article-title":"Planning a method for covariate adjustment in individually randomised trials: a practical guide","volume":"23","author":"Morris","year":"2022","journal-title":"Trials"},{"issue":"1","key":"2026031905361598800_ref21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/aje\/kwq084","article-title":"Generalizing evidence from randomized clinical trials to target populations: the ACTG 320 trial","volume":"172","author":"Cole","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"4","key":"2026031905361598800_ref22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/ede.0000000000000664","article-title":"Generalizing study results: a potential outcomes perspective","volume":"28","author":"Lesko","year":"2017","journal-title":"Epidemiology"},{"issue":"8","key":"2026031905361598800_ref23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/aje\/kwx164","article-title":"Transportability of trial results using inverse odds of sampling weights","volume":"186","author":"Westreich","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"12","key":"2026031905361598800_ref24","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1093\/aje\/kwab231","article-title":"Twister plots for time-to-event studies","volume":"190","author":"Zivich","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2026031905361598800_ref25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2307\/2531492","article-title":"Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data","volume":"45","author":"Pepe","year":"1989","journal-title":"Biometrics"},{"issue":"2","key":"2026031905361598800_ref26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.2517-6161.1991.tb01827.x","article-title":"Weighted Kaplan-Meier statistics: large sample and optimality considerations","volume":"53","author":"Pepe","year":"1991","journal-title":"J R Stat Soc B Methodol"},{"issue":"4","key":"2026031905361598800_ref27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1177\/1740774509338231","article-title":"Nonparametric estimator of relative time with application to the Acyclovir Prevention Trial","volume":"6","author":"Cole","year":"2009","journal-title":"Clin Trials"},{"issue":"6","key":"2026031905361598800_ref28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nmeth.3414","article-title":"Sampling distributions and the bootstrap","volume":"12","author":"Kulesa","year":"2015","journal-title":"Nat Methods"},{"issue":"28","key":"2026031905361598800_ref29","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"6","key":"2026031905361598800_ref30","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26118","article-title":"Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women","volume":"26","author":"Donnell","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"2026031905361598800_ref31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"issue":"8","key":"2026031905361598800_ref32","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/sim.9296","article-title":"Statistical considerations for cross-sectional HIV incidence estimation based on recency test","volume":"41","author":"Gao","year":"2022","journal-title":"Stat Med"},{"issue":"1","key":"2026031905361598800_ref33","doi-asserted-by":"publisher","DOI":"10.1515\/scid-2020-0009","article-title":"Sample size calculation for active-arm trial with counterfactual incidence based on recency assay","volume":"13","author":"Gao","year":"2021","journal-title":"Stat Commun Infect Dis"},{"issue":"5","key":"2026031905361598800_ref34","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25744","article-title":"Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial","volume":"24","author":"Glidden","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"2026031905361598800_ref35","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1016\/S2352-3018(20)30192-2","article-title":"A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial","volume":"7","author":"Glidden","year":"2020","journal-title":"Lancet HIV"},{"issue":"10","key":"2026031905361598800_ref36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/aje\/kwv200","article-title":"Invited commentary: every good randomization deserves observation","volume":"182","author":"Westreich","year":"2015","journal-title":"Am J Epidemiol"},{"key":"2026031905361598800_ref37","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2211.04876","article-title":"Generalizing and transporting inferences about the effects of treatment assignment subject to non-adherence","author":"Dahabreh","year":"9, 2022"},{"issue":"6","key":"2026031905361598800_ref38","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/EDE.0000000000000160","article-title":"The parametric G-formula for time-to-event data: towards intuition with a worked example","volume":"25","author":"Keil","year":"2014","journal-title":"Epidemiology"},{"issue":"2","key":"2026031905361598800_ref39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1467-985X.2010.00673.x","article-title":"The use of propensity scores to assess the generalizability of results from randomized trials","volume":"174","author":"Stuart","year":"2011","journal-title":"J R Stat Soc A Stat Soc"},{"issue":"3","key":"2026031905361598800_ref40","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/EDE.0000000000001177","article-title":"Toward causally interpretable meta-analysis: transporting inferences from multiple randomized trials to a new target population","volume":"31","author":"Dahabreh","year":"2020","journal-title":"Epidemiology"},{"issue":"4","key":"2026031905361598800_ref41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4&lt;361::AID-SIM168&gt;3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"issue":"1","key":"2026031905361598800_ref42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pst.1589","article-title":"Use of historical control data for assessing treatment effects in clinical trials","volume":"13","author":"Viele","year":"2014","journal-title":"Pharm Stat"},{"issue":"5","key":"2026031905361598800_ref43","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/pst.2009","article-title":"Revisit of test-then-pool methods and some practical considerations","volume":"19","author":"Li","year":"2020","journal-title":"Pharm Stat"},{"issue":"9119","key":"2026031905361598800_ref44","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"2026031905361598800_ref45","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2305.00845","article-title":"Fusing trial data for treatment comparisons: single versus multi-span bridging","author":"Shook-Sa","year":"1, 2023"},{"issue":"7","key":"2026031905361598800_ref46","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/aje\/kwad077","article-title":"Introducing proximal causal inference for epidemiologists","volume":"192","author":"Zivich","year":"2023","journal-title":"Am J Epidemiol"},{"key":"2026031905361598800_ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/9781118445112.stat08068","volume-title":"Wiley StatsRef: Statistics Reference Online","author":"Daniel","year":"2018"},{"key":"2026031905361598800_ref48","doi-asserted-by":"publisher","DOI":"10.1002\/9781118445112.stat06031","volume-title":"Wiley StatsRef: Statistics Reference Online","author":"Rotnitzky","year":"2014"},{"issue":"3","key":"2026031905361598800_ref49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/EDE.0000000000001332","article-title":"Machine learning for causal inference: on the use of cross-fit estimators","volume":"32","author":"Zivich","year":"2021","journal-title":"Epidemiology"},{"issue":"9","key":"2026031905361598800_ref50","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/aje\/kwab201","article-title":"Challenges in obtaining valid causal effect estimates with machine learning algorithms","volume":"192","author":"Naimi","year":"2021","journal-title":"Am J Epidemiol"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwae340\/58986164\/kwae340.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/6\/1687\/58986164\/kwae340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/6\/1687\/58986164\/kwae340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:36:22Z","timestamp":1773912982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/194\/6\/1687\/7746748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8,31]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwae340","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,8,31]]}}}